Regulatory Watch
June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022 June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022

ProHealth Longevity

www.prohealthlongevity.com ↗
Founded: 1988 HQ: Carpinteria, California Last reviewed: February 20, 2026
B-
Overall Grade
Transparency 70/100
Testing 65/100
Pricing 60/100
Reputation 65/100
Compliance 80/100
Publishes COA Yes
Third-Party Testing Yes
FDA Warning Letters 0
Product Types oral-capsule, powder

Company Overview

ProHealth Longevity was founded in 1988 by Rich Carson in Carpinteria, California, making it one of the longest-operating supplement companies in the market at 36 years. The company is primarily focused on NMN, NAD+ precursors, and longevity supplements — peptides represent a small part of their product line. Estimated revenue: $50–100M. BBB: A+ (accredited since 2019).

Products & Pricing

ProHealth is not a peptide specialist. Their core product lines are NMN, NAD+ boosters, and general longevity supplements. If they offer peptide products, they’re positioned alongside a broader supplement catalog rather than as a peptide-focused vendor.

Pricing is generally competitive within the mainstream supplement market, though not the cheapest option available.

Transparency Assessment

Score: 70/100 — ProHealth has a stronger transparency track record than most competitors. As an established, BBB-accredited company with 36 years of operation, they have a level of institutional accountability that newer peptide-focused vendors lack. Third-party testing claims appear more credible given the company’s longevity and regulatory track record.

Testing & Quality

Score: 65/100 — Claims third-party testing and has been in business long enough to have developed quality systems. However, specific documentation around peptide product testing (vs. their core supplement lines) may be less robust.

Regulatory Standing

Score: 80/100 — No FDA warning letters found. No regulatory actions identified. BBB A+ rating with accreditation since 2019. The clean 36-year regulatory record is a genuine strength and a meaningful differentiator in a market full of companies that are 2–5 years old.

Customer Experience

Score: 65/100 — Mixed picture. Trustpilot shows approximately 2.6–2.8/5 from ~25 reviews, with recurring customer service complaints. However, Judge.me shows 4.8/5 from 10,446 reviews — though solicited reviews from on-site widgets tend to skew positive. The disconnect between platforms suggests decent products but potentially inconsistent customer service.

Red Flags

  1. Not a peptide specialist: Their expertise is in NMN/longevity supplements, not peptide formulation
  2. Customer service complaints: Recurring Trustpilot feedback about responsiveness
  3. Review platform discrepancy: Large gap between Trustpilot and Judge.me scores warrants caution

The Bottom Line

ProHealth Longevity’s primary strengths are institutional — 36 years in business, BBB A+ accreditation, and a clean regulatory record are genuine differentiators in the peptide/supplement market. The company is not a peptide specialist, which means their expertise and formulation focus lies elsewhere. If you’re looking for a vendor with proven institutional stability and regulatory compliance, ProHealth scores well. If you’re looking for deep peptide expertise and formulation innovation, this isn’t the primary focus of their business.